Comparison between effectiveness of two different molecular weights of hyaluronic acid on shoulder tendinopathy.

A Comparison between subacromial space injections of Low Molecular Weight Hyaluronic Acid (Hyalgan® MW= 500-700 KD) and High Molecular Weight Hyaluronic Acid (Synogel® MW>2000 KD) in Rotator Cuff Tendinopathy.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170608034390N5

Enrollment

Registered

2020-01-16

Start date

2018-06-22

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotator cuff tendinopathy. Unsp rotatr-cuff tear/ruptr of left shoulder, not trauma.

Interventions

Intervention 1: Intervention group: High MW of Hyaluronic acid (Synogel® MW>2000 KD) injection in subacromial space of shoulder with Codman's (pendulum) Exercises. Intervention 2: Intervention group:

Eligibility

Sex/Gender

All

Age

16 Years to 70 Years

Inclusion criteria

Inclusion criteria: Tendinopathy of Rotator Cuff ?Adults (16-70 years) At least 6 weeks from the onset of pain

Exclusion criteria

Exclusion criteria: Pregnant or lactating Women Active systemic rheumatologic disorders Coagulopathies or on anticoagulant medication Diabetes mellitus Active septic disorders or history of cancers or tumors around the site of shoulder joint Use of systemic corticosteroid drugs recently in one month

Design outcomes

Primary

Measure	Time frame
Pain intensity based on visual analogue scale. Timepoint: Measuring the severity of pain at the beginning of the study (before the intervention), one week, one month and three months after the injection. Method of measurement: Visual Analogue Scale (VAS).	—

Secondary

Measure	Time frame
Range of Motion (ROM). Timepoint: Measuring the range of motion at the beginning of the study (before the intervention), one week, one month and three months after the injection. Method of measurement: Goniometer.;Adverse events (e.g., Inflammation in the injection site). Timepoint: Inflammation in the injection site at the first week of study after the injection. Method of measurement: Hyperemia, warmth, pain, tendonitis, tenderness.;The disabilities of the arm, shoulder and hand. Timepoint: Measuring the disabilities of the arm, shoulder and hand at the beginning of the study (before the intervention), one week, one month and three months after the injection. Method of measurement: The Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire.;Quality of life. Timepoint: Measuring the Quality of life at the beginning of the study (before the intervention), one week, one month and three months after the injection. Method of measurement: QOL-BREF Questionnaire.	—

Measure

Time frame

Range of Motion (ROM). Timepoint: Measuring the range of motion at the beginning of the study (before the intervention), one week, one month and three months after the injection. Method of measurement: Goniometer.;Adverse events (e.g., Inflammation in the injection site). Timepoint: Inflammation in the injection site at the first week of study after the injection. Method of measurement: Hyperemia, warmth, pain, tendonitis, tenderness.;The disabilities of the arm, shoulder and hand. Timepoint: Measuring the disabilities of the arm, shoulder and hand at the beginning of the study (before the intervention), one week, one month and three months after the injection. Method of measurement: The Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire.;Quality of life. Timepoint: Measuring the Quality of life at the beginning of the study (before the intervention), one week, one month and three months after the injection. Method of measurement: QOL-BREF Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Esmaily

Shahid Beheshti University of Medical Sciences

Esmaily_hadi@sbmu.ac.ir+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026